题名 | Targeting Nitric Oxide Production in Microglia with Novel Imidazodiazepines for Nonsedative Pain Treatment |
作者 | |
发表日期 | 2020-07-01
|
DOI | |
发表期刊 | |
ISSN | 1948-7193
|
EISSN | 1948-7193
|
卷号 | 11期号:13页码:2019-2030 |
摘要 | The goal of this research is the identification of new treatments for neuropathic pain. We characterized the GABAergic system of immortalized mouse and human microglia using electrophysiology and qRT-PCR. Cells from both species exhibited membrane current changes in response to γ-aminobutyric acid, with an EC50 of 260 and 1940 nM, respectively. Human microglia expressed high levels of the γ-aminobutyric acid type A receptor (GABAAR) α3 subunit, which can assemble with β1 and γ2/δ subunits to form functional GABAARs. Mouse microglia contained α2, α3, and α5, in addition to β1-3, γ1-2, and δ, mRNA, enabling a more diverse array of GABAARs than human microglia. Benzodiazepines are well-established modulators of GABAAR activity, prompting a screen of a library of diverse benzodiazepines in microglia for cellular effects. Several active compounds were identified by reduction of nitric oxide (NO) in interferon gamma and lipopolysaccharide activated microglia. However, further investigation with GABAAR antagonists flumazenil, picrotoxin, and bicuculline demonstrated that GABAARs were not linked to the NO response. A screen of 48 receptors identified the κ-opioid receptor and to a lesser extent the μ-opioid receptor as molecular targets, with opioid receptor antagonist norbinaltorphimine reversing benzodiazepine induced reduction of microglial NO. Functional assays identified the downregulation of inducible NO synthase as the mode of action of imidazodiazepines MP-IV-010 and GL-IV-03. Like other κ-opioid receptor agonists, GL-IV-03 reduced the agitation response in both phases of the formalin nociception test. However, unlike other κ-opioid receptor agonists, MP-IV-010 and GL-IV-03 did not impair sensorimotor coordination in mice. Thus, MP-IV-010 and GL-IV-03 represent a new class of nonsedative drug candidates for inflammatory pain. |
关键词 | |
相关链接 | [Scopus记录] |
收录类别 | |
语种 | 英语
|
学校署名 | 其他
|
资助项目 | National Institutes of Health (USA)[R41HL147658][R01NS076517][R01HL118561]
; National Science Foundation, Division of Chemistry[CHE-1625735]
|
WOS研究方向 | Biochemistry & Molecular Biology
; Pharmacology & Pharmacy
; Neurosciences & Neurology
|
WOS类目 | Biochemistry & Molecular Biology
; Chemistry, Medicinal
; Neurosciences
|
WOS记录号 | WOS:000547324200020
|
出版者 | |
Scopus记录号 | 2-s2.0-85087466986
|
来源库 | Scopus
|
引用统计 |
被引频次[WOS]:5
|
成果类型 | 期刊论文 |
条目标识符 | http://sustech.caswiz.com/handle/2SGJ60CL/140699 |
专题 | 理学院_化学系 深圳格拉布斯研究院 |
作者单位 | 1.Department of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery,University of Wisconsin-Milwaukee,Milwaukee,53201,United States 2.Shenzhen Grubbs Institute and Department of Chemistry,Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis,Southern University of Science and Technology,Shenzhen,518055,China 3. 4.Department of Chemistry,Western Michigan University,Kalamazoo,49008,United States 5.Department of Molecular Biology and Microbiology,Case Western Reserve University,Cleveland,44106,United States |
推荐引用方式 GB/T 7714 |
Nieman,Amanda N.,Li,Guanguan,Zahn,Nicolas M.,et al. Targeting Nitric Oxide Production in Microglia with Novel Imidazodiazepines for Nonsedative Pain Treatment[J]. ACS Chemical Neuroscience,2020,11(13):2019-2030.
|
APA |
Nieman,Amanda N..,Li,Guanguan.,Zahn,Nicolas M..,Mian,Md Yeunus.,Mikulsky,Brandon N..,...&Arnold,Leggy A..(2020).Targeting Nitric Oxide Production in Microglia with Novel Imidazodiazepines for Nonsedative Pain Treatment.ACS Chemical Neuroscience,11(13),2019-2030.
|
MLA |
Nieman,Amanda N.,et al."Targeting Nitric Oxide Production in Microglia with Novel Imidazodiazepines for Nonsedative Pain Treatment".ACS Chemical Neuroscience 11.13(2020):2019-2030.
|
条目包含的文件 | 条目无相关文件。 |
|
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论